Program
remigromig
Its studies are mostly in Macular Edema · Macular Degeneration · Retinal Vein Occlusion, led by Merck.
Furthest: phase 3, since Aug 20, 20244 company-led studies, 3 open or runningNext primary completion: Jan 11, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 43 open or running | phase 3since Aug 20, 2024 | Jun 14, 2023 | Jan 11, 2027phase 3 · NCT06957080 |
- Named in Merck’s own pipeline as
remigromig (MK-3000)
, phase 3, as of Nov 2, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 14, 2023First study: phase 2 study in Macular DegenerationFirst studyNCT05919693 · 33 enrolled · United States, Argentina, Puerto Rico and more
- Aug 20, 2024Phase 3 study in Diabetic Macular Edema (DME)NCT06571045 · 984 enrolled · United States, Argentina, Australia and more
- Apr 16, 2025Phase 3 study in Diabetic Macular Edema (DME)NCT06957080 · 1,054 enrolled · United States, Argentina, Brazil and more
- Sep 24, 2025Phase 2 study in Retinal Vein OcclusionNCT07205887 · 160 planned · United States
Ahead
- Jan 11, 2027Primary completion: phase 3 study in Diabetic Macular Edema (DME)NCT06957080
- Jun 30, 2028Primary completion: phase 2 study in Retinal Vein OcclusionNCT07205887
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07205887Retinal Vein Occlusion · United States | 2 | Recruiting | Jun 30, 2028 | 160 |
| NCT06957080Diabetic Macular Edema (DME) · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Jan 11, 2027 | 1,054 |
| NCT06571045Diabetic Macular Edema (DME) · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 14, 2026 | 984 |
| NCT05919693Macular Degeneration · United States, Argentina, Puerto Rico and more | 2 | Completed | Aug 26, 2024 | 33 |
How it is read
Names in the registry
- “Remigromig”, 4 entries
Conditions, from the studies’ own filings
- Macular Edema, 2 studies
- Macular Degeneration, 1 study
- Retinal Vein Occlusion, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.